These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23351576)

  • 1. From the editor: selling the benefit of drug therapy.
    Brown WV
    J Clin Lipidol; 2013; 7(1):1-2. PubMed ID: 23351576
    [No Abstract]   [Full Text] [Related]  

  • 2. Illuminating HDL--is it still a viable therapeutic target?
    Rader DJ
    N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168
    [No Abstract]   [Full Text] [Related]  

  • 3. HDL-cholesterol levels and cardiovascular risk: acCETPing the context.
    Lange RA; Lindsey ML
    Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471
    [No Abstract]   [Full Text] [Related]  

  • 4. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 5. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
    Taylor J
    Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754
    [No Abstract]   [Full Text] [Related]  

  • 6. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and biophysical insight into cholesteryl ester-transfer protein.
    Hall J; Qiu X
    Biochem Soc Trans; 2011 Aug; 39(4):1000-5. PubMed ID: 21787337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viability of developing CETP inhibitors.
    Sirtori CR; Mombelli G
    Cardiovasc Ther; 2008; 26(2):135-46. PubMed ID: 18485135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
    Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073
    [No Abstract]   [Full Text] [Related]  

  • 12. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the editor: what are the important questions for clinical trials?
    Brown WV
    J Clin Lipidol; 2012; 6(4):299-300. PubMed ID: 22836064
    [No Abstract]   [Full Text] [Related]  

  • 15. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction.
    Gutstein DE; Krishna R; Johns D; Surks HK; Dansky HM; Shah S; Mitchel YB; Arena J; Wagner JA
    Clin Pharmacol Ther; 2012 Jan; 91(1):109-22. PubMed ID: 22130116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The failure of torcetrapib: was it the molecule or the mechanism?
    Tall AR; Yvan-Charvet L; Wang N
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel strategies to control lipid metabolism: can the antisense drug mipomersen fulfill the unmet need?
    Merk D; Schubert-Zsilavecz M
    Future Med Chem; 2012 Sep; 4(14):1773-5. PubMed ID: 23043473
    [No Abstract]   [Full Text] [Related]  

  • 18. HDL: still a target for new therapies?
    Nicholls SJ
    Curr Opin Investig Drugs; 2008 Sep; 9(9):950-6. PubMed ID: 18729001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.